ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

ZUARI AGRO CHEMICALS-Rise in Fertiliser Demand

(MMD) in July this year at a cost of $ 7.1 billion. With this acquisition, Hoechst Marion Roussel. as the new merged entity is to be called, will enhance its worldwide presence, particularly in North America. The two pharmaceutical multinationals in India Hoechst and Roussel will come under a common management and bring new products from Marion Merrel Dow into the country. Roussel is now a subsidiary of Hoechst India but operates separately. A plan to closely integrate the working of the two companies is being drawn up. While Hoechst India has 66 per cent stake in Roussel India, the other 33 per cent is with Roussel Uclaf of France. Hoechst AC has 50 1 per cent in Hoechst India, with another 28 per cent being owned by Vijay Mallya. The MMD products that may be co-marketed by Hoechst and Roussel are rifampicin, diltiazem, terfenedine and vegabatrin, thereby posing a likely challenge to Lupin which is the market leader in rifampicin. With combined sales estimated at $ 10 billion. Hoechst Marion Roussel (HMR) will be one of the world's largest pharmaceutical organisations and will concentrate on cardiovascular and anti-infective and metabolic drugs. Hoechst India spent 2.5 per cent of its annual turnover on R and D in 1994-95. According to Werner Badziong, research director of Hoechst India, the company is currently engaged in research in anti-infec- tives, cardiovascular drugs, alternative treatment for diabetes and treatment for arthritis. The acquisition of MMD which spends a major portion of its sales turnover on research will be beneficial to Hoechst and Roussel products in India, it is claimed. In 1994, MMD spent around 15 per cent of its sales turnover of $ 3.1 billion on research.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now


(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top